The Auckland medical device firm’s shares sold as high as 16 cents, before closing up 4c at 14. The firmmakes a device it believes could be a viable alternative to Pap smear tests.
Truscreen in demand – Timaru Herald
Truscreen’s shares have debuted on the NZX’s alternative market, the NZAX, at a 60 per cent premium to their pre-float price.